Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors

Clinical trial NCT04337177 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT04337177
Sponsor: Valent Technologies, LLC
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Solid Tumors Neuroblastoma Rhabdomyosarcoma Ewing Sarcoma Hepatoblastoma Medulloblastoma

Start date: 2021-10-25
Primary completion: 2026-12-01
Enrollment: 20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.